Mirae Asset Global Investments Has Trimmed By $418,500 Its Heron Therapeutics (HRTX) Stake; VODACOM GROUP LTD ORDINARY SHARES S (VODAF) Shorts Raised By 2.51%

Mirae Asset Global Investments decreased Heron Therapeutics Inc (HRTX) stake by 12.33% reported in 2018Q3 SEC filing. Mirae Asset Global Investments sold 13,500 shares as Heron Therapeutics Inc (HRTX)’s stock declined 28.09%. The Mirae Asset Global Investments holds 96,000 shares with $3.04M value, down from 109,500 last quarter. Heron Therapeutics Inc now has $2.06B valuation. The stock decreased 5.18% or $1.44 during the last trading session, reaching $26.45. About 492,374 shares traded. Heron Therapeutics, Inc. (NASDAQ:HRTX) has risen 74.30% since February 13, 2018 and is uptrending. It has outperformed by 74.30% the S&P500. Some Historical HRTX News: 19/03/2018 – HERON THERAPEUTICS INC – SIGNIFICANTLY FEWER HTX-011 PATIENTS EXPERIENCED SEVERE PAIN AT ANY TIME; 10/04/2018 – Blue Heron Bakery | Seattle District Office | CGMP Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated; 19/03/2018 – HERON THERAPEUTICS INC – SIGNIFICANTLY MORE PATIENTS RECEIVING HTX-011 WERE OPIOID-FREE THROUGH 72 HOURS AFTER SURGERY; 07/05/2018 – Recro Pharma Announces Receipt of Issue Notifications for Three New Patents for IV Meloxicam; 27/03/2018 – Recro Pharma Announces Publication of Phase lll IV Meloxicam Bunionectomy Data in the Clinical Journal of Pain; 19/03/2018 – HERON: NDA FILING TARGETED FOR 2H 2018; 27/03/2018 – Recro Pharma Announces Publication of Phase III IV Meloxicam Bunionectomy Data in the Clinical Journal of Pain; 24/05/2018 – RECRO PHARMA INC – RECEIVED CRL FROM FDA OFFICE OF DRUG EVALUATION Il REGARDING NEW DRUG APPLICATION (NDA) FOR IV MELOXICAM; 04/04/2018 – Work Capital Announces New Partnership with the Heron Foundation; 22/04/2018 – DJ Heron Therapeutics Inc, Inst Holders, 1Q 2018 (HRTX)

VODACOM GROUP LTD ORDINARY SHARES S (OTCMKTS:VODAF) had an increase of 2.51% in short interest. VODAF’s SI was 122,600 shares in February as released by FINRA. Its up 2.51% from 119,600 shares previously. With 400 avg volume, 307 days are for VODACOM GROUP LTD ORDINARY SHARES S (OTCMKTS:VODAF)’s short sellers to cover VODAF’s short positions. It closed at $8.7 lastly. It is down 0.00% since February 13, 2018 and is . It has by 0.00% the S&P500.

More notable recent Heron Therapeutics, Inc. (NASDAQ:HRTX) news were published by: Seekingalpha.com which released: “Heron President to retire – Seeking Alpha” on February 05, 2019, also Benzinga.com with their article: “40 Stocks Moving In Friday’s Pre-Market Session – Benzinga” published on January 18, 2019, Globenewswire.com published: “New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019 – GlobeNewswire” on January 30, 2019. More interesting news about Heron Therapeutics, Inc. (NASDAQ:HRTX) were released by: Nasdaq.com and their article: “RSI Alert: Heron Therapeutics (HRTX) Now Oversold – Nasdaq” published on September 20, 2018 as well as Nasdaq.com‘s news article titled: “Heron Therapeutics Inc. (HRTX) Is Surging On FDA Priority Review – Nasdaq” with publication date: December 31, 2018.

Analysts await Heron Therapeutics, Inc. (NASDAQ:HRTX) to report earnings on February, 26. They expect $-0.47 EPS, up 56.88% or $0.62 from last year’s $-1.09 per share. After $-0.49 actual EPS reported by Heron Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -4.08% EPS growth.

Mirae Asset Global Investments increased Symantec Corp (NASDAQ:SYMC) stake by 117,454 shares to 348,048 valued at $7.40M in 2018Q3. It also upped Skyworks Solutions Inc (NASDAQ:SWKS) stake by 67,495 shares and now owns 80,472 shares. D R Horton Inc (NYSE:DHI) was raised too.

Vodacom Group Limited, a unified communications provider, offers mobile voice, messaging, data, financial, and converged services to the consumer, business, and enterprise clients in South Africa and internationally. The company has market cap of $15.52 billion. The Company’s services cover managed connectivity, converged communications, connectivity and network, fixed-line and wireless connections, Internet and virtual private network, hosted cloud, enterprise mobility, unified communication, machine to machine communications, broadband, track and monitor, mHealth, and mEducation, as well as wireless, fixed-line, satellite, mobile, and converged solutions. It currently has negative earnings. The firm was founded in 1993 and is headquartered in Midrand, South Africa.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Ratings Chart